Northwestern University

Mon 4:00 PM

Pharmacology Research Works-in-Progress: Eugene Wyatt, Ph.D. and Tanima De, Ph.D.

When: Monday, February 4, 2019
4:00 PM - 5:00 PM  

Where: Ward Building, 5-230, 303 E. Chicago Avenue, Chicago, IL 60611 map it

Audience: Faculty/Staff - Student - Post Docs/Docs - Graduate Students

Contact: Alexa Nash   312.503.4893

Group: Department of Pharmacology Seminars

Category: Lectures & Meetings


Eugene Wyatt, Ph.D.
Research Assistant Professor of Pharmacology

"Generating Mouse Models Through the Northwestern TTML"

Genetically modified mice are essential research tools used to understand gene function and model disease. The advent of CRISPR gene editing technology has revolutionized the process of generating mouse models, reducing costs and improving efficiency. The Northwestern University Transgenic and Targeted Mutagenesis Laboratory (TTML) has extensive experience using the most cutting-edge CRISPR gene editing techniques to generate genetically modified mice. This includes knock-outs, point mutations, insertion of epitope tags, and conditional alleles. The TTML offers project design consultation, and can target mutations in embryos and embryonic stem cells. In addition, the TTML offers a comprehensive range of services for the Northwestern community.

Tanima De, Ph.D.
Postdoctoral Fellow, Dr. Minoli Perera Laboratory

"Genetic Basis of Pharmacokinetic Variability in African Americans"

Genetic variation contributes substantially to the differences in drug response observed within and across populations. African Americans suffer disproportionately from many chronic diseases and adverse drug reactions. Exploring the unique genomic architecture of African Americans can reveal population-specific risk factors that may explain health disparity in drug response. Hepatic cytochrome P450 enzymes account for more than 95% of the phase 1 metabolism of all drugs. We used primary hepatocyte suspension cultures derived from 60 African American non-diseased livers to study genetic basis of pharmacokinetic variability of cytochrome P450 enzymes specific probe drugs. We identified common and population-specific genetic variants that were significantly associated with pharmacokinetic variability. Functional mapping revealed their potentially regulated genes that may play an important role in the regulation of cytochrome P450 enzyme expression. The identified genetic variants therefore may represent causative variants that predispose individuals to adverse events related to several different medications. Our findings may help towards predicting adverse drug events and improving dosage therapy and treatment outcomes in African Americans.

Add Event to Calendar

Add Event To My Group:

Please sign-in